Characteristics of known drug space. Natural products, their derivatives and synthetic drugs.
暂无分享,去创建一个
[1] G. Rishton. Reactive compounds and in vitro false positives in HTS , 1997 .
[2] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[3] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[4] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[5] Kristina Luthman,et al. Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans , 1997, Pharmaceutical Research.
[6] Jóhannes Reynisson,et al. Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds. , 2009, European journal of medicinal chemistry.
[7] A. Nassar,et al. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. , 2004, Drug discovery today.
[8] Jóhannes Reynisson,et al. Benchmarking the reliability of QikProp. Correlation between experimental and predicted values , 2008 .
[9] Li Xing,et al. Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. , 2004, Journal of medicinal chemistry.
[10] Thomas Henkel,et al. Statistical Investigation into the Structural Complementarity of Natural Products and Synthetic Compounds. , 1999, Angewandte Chemie.
[11] D. Newman,et al. Impact of natural products on developing new anti-cancer agents. , 2009, Chemical reviews.
[12] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[13] Maurice Dickins,et al. Compound lipophilicity for substrate binding to human P450s in drug metabolism. , 2004, Drug discovery today.
[14] Christopher P Austin,et al. Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. , 2010, Journal of medicinal chemistry.
[15] J. Li. Laughing Gas, Viagra, and Lipitor: The Human Stories behind the Drugs We Use , 2006 .
[16] D J Newman,et al. Natural products in drug discovery and development. , 1997, Journal of natural products.
[17] M. A. Meyers. Happy Accidents: Serendipity in Modern Medical Breakthroughs , 2007 .
[18] Walter Sneader,et al. Drug Discovery (The History) , 2005 .
[19] P. Leeson,et al. A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.
[20] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[21] Jóhannes Reynisson,et al. Known drug space as a metric in exploring the boundaries of drug-like chemical space. , 2009, European journal of medicinal chemistry.
[22] G. Schwartsmann,et al. Natural products in anticancer therapy. , 2001, Current opinion in pharmacology.
[23] John L. LaMattina,et al. Book Review: Drug Truths: Dispelling the Myths About Pharma R&D , 2008 .
[24] David J Newman,et al. Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.
[25] B. Shoichet,et al. A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.
[26] Miklos Feher,et al. Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry , 2003, J. Chem. Inf. Comput. Sci..
[27] P. Hajduk,et al. Cheminformatic tools for medicinal chemists. , 2010, Journal of medicinal chemistry.
[28] M. Gleeson. Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.
[29] D. E. Clark. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. , 1999, Journal of pharmaceutical sciences.
[30] M. Waring,et al. A quantitative assessment of hERG liability as a function of lipophilicity. , 2007, Bioorganic & medicinal chemistry letters.
[31] P. Clemons,et al. Distinct Biological Network Properties between the Targets of Natural Products and Disease Genes , 2010, Journal of the American Chemical Society.
[32] J. Vederas,et al. Drug Discovery and Natural Products: End of an Era or an Endless Frontier? , 2009, Science.
[33] G. Rishton. Nonleadlikeness and leadlikeness in biochemical screening. , 2003, Drug discovery today.
[34] D. Newman,et al. Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.
[35] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[36] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.